COFCO Biotechnology Co., Ltd. (SHE:000930)
China · Delayed Price · Currency is CNY 6.08
+0.05 (0.83%)
Apr 30, 2026, 3:04 PM CST
COFCO Biotechnology Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | -115.75 | 46.23 | 25.13 | -601.63 | 1,059 | 1,130 |
Depreciation & Amortization | 516.69 | 516.69 | 501.96 | 491.84 | 458.19 | 449.81 |
Other Amortization | 16.46 | 16.46 | 24.44 | 17.37 | 17.96 | 20.79 |
Loss (Gain) From Sale of Assets | -60.1 | -60.1 | 0.15 | -1.16 | 145.82 | 203.22 |
Asset Writedown & Restructuring Costs | 495.93 | 495.93 | 2.27 | 54.45 | 13.3 | 21.48 |
Loss (Gain) From Sale of Investments | -35.1 | -35.1 | -42.25 | 10.33 | 4.08 | -41.92 |
Provision & Write-off of Bad Debts | - | - | 35.97 | -0.15 | 0.21 | 0.21 |
Other Operating Activities | -425.24 | 88.29 | 546.17 | 641.07 | 278.15 | 347.89 |
Change in Accounts Receivable | 326.97 | 326.97 | -199.05 | 1,011 | -1,052 | 2,418 |
Change in Inventory | 433.37 | 433.37 | -653.64 | 679.83 | 83.07 | 760.34 |
Change in Accounts Payable | 74.79 | 74.79 | -42.82 | -287.46 | -329.12 | -414.53 |
Change in Other Net Operating Assets | - | - | -4.86 | -14.35 | -6.27 | 8.67 |
Operating Cash Flow | 1,172 | 1,847 | 155.81 | 1,958 | 708.44 | 4,842 |
Operating Cash Flow Growth | -10.81% | 1085.69% | -92.04% | 176.38% | -85.37% | - |
Capital Expenditures | -737.98 | -673.93 | -483.3 | -634.52 | -565.78 | -1,110 |
Sale of Property, Plant & Equipment | 65.42 | 61.44 | 16.44 | 166.32 | 246.92 | 270.39 |
Divestitures | - | - | - | - | - | 160.52 |
Investment in Securities | 102.85 | 102.85 | - | - | 5.6 | - |
Other Investing Activities | 147.64 | 41.82 | 90.22 | -104.8 | 12.68 | 10.96 |
Investing Cash Flow | -422.07 | -467.82 | -376.64 | -572.99 | -300.58 | -667.9 |
Long-Term Debt Issued | - | 6,969 | 6,877 | 7,565 | 6,437 | 8,253 |
Long-Term Debt Repaid | - | -7,663 | -6,115 | -7,275 | -6,521 | -11,627 |
Net Debt Issued (Repaid) | -562.59 | -693.44 | 761.5 | 289.33 | -84.59 | -3,374 |
Common Dividends Paid | -71.17 | -83.06 | -93.48 | -1,172 | -554.75 | -277.34 |
Other Financing Activities | -15.04 | -11.09 | -156.58 | 2.91 | 45.05 | -50.03 |
Financing Cash Flow | -648.79 | -787.6 | 511.45 | -880.04 | -594.28 | -3,702 |
Foreign Exchange Rate Adjustments | -31.64 | 21.72 | 27.52 | 11.07 | 40.37 | -4.32 |
Net Cash Flow | 69.46 | 613.75 | 318.14 | 516.02 | -146.05 | 467.69 |
Free Cash Flow | 433.97 | 1,174 | -327.49 | 1,323 | 142.66 | 3,732 |
Free Cash Flow Growth | -48.17% | - | - | 827.69% | -96.18% | - |
Free Cash Flow Margin | 2.55% | 6.70% | -1.63% | 6.49% | 0.72% | 15.84% |
Free Cash Flow Per Share | 0.23 | 0.63 | -0.18 | 0.72 | 0.08 | 2.02 |
Cash Income Tax Paid | 266.94 | 266.94 | 291.39 | 214.77 | 227.63 | 603.27 |
Levered Free Cash Flow | 2,308 | 2,791 | -400.99 | 1,267 | 192.1 | 3,071 |
Unlevered Free Cash Flow | 2,308 | 2,791 | -335.45 | 1,337 | 246.55 | 3,170 |
Change in Working Capital | 779.07 | 779.07 | -938.03 | 1,346 | -1,268 | 2,711 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.